High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV‐infected patients treated in a real‐life setting

Fabbiani, Massimiliano; Lombardi, Andrea; Colaneri, Marta; Poggio, P. Del; Perini, Paolo; D’Ambrosio, Roberta; Degasperi, Elisabetta; Giorgini, Alessia; Pasulo, L.; Maggiolo, Franco; Castelli, Francesco; Brambilla, Paola; Spinelli, Ombretta; Re, T.; Lleo, Ana; Rumi, M.G.; Uberti‐Foppa, Caterina; Soria, Alessandro; Aghemo, Alessio; Lampertico, Pietro; Baiguera, Chiara; Schiavini, Monica; Fagiuoli, S.; Bruno, Raffaele

doi:10.1111/jvh.13454

Cited by 7 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison to previous studies, good adherence to treatment and the follow-up program was observed in our series, with no drop-outs due to toxicity[ 21 - 25 ]. In particular, Avramovic et al [ 24 ] reported a similar rate of virological response (92%) in PWIDs.…”

Section: Discussionsupporting

confidence: 49%

Hepatitis C virus burden: Treating and educating people without prejudice

Merola¹,

Menotti²,

Branz³

et al. 2022

WJH

View full text Add to dashboard Cite

BACKGROUND Hepatitis C virus (HCV) infection has a worldwide incidence of 1.1%. In Italy, 60% of people who inject drugs (PWIDs) and are receiving assistance for substance use disorder are infected with HCV. However, this subset of patients has extremely limited access to care due to multiple factors, including alcohol abuse, psychological comorbidities, and homeless status. AIM To describe the impact of our HCV-dedicated service for substance use disorder (SSUD) service on PWIDs receiving anti-HCV therapy. METHODS A dedicated, multidisciplinary team was set up at the SSUD of Trento in October 2020 to provide antiviral treatment to HCV RiboNucleic Acid-positive patients with an active or previous history of substance abuse. The treatment was followed by a health education program. Patients were treated with Direct-Acting Antivirals (DAAs). Data were retrospectively analyzed to assess the efficacy of our dedicated program in terms of therapy completion, HCV eradication, and compliance (primary endpoint). The rate of HCV reinfection and DAA-related toxicity were also assessed (secondary endpoints). RESULTS A total of 40 patients were enrolled in the study: 28 (70.0%) were treated with Sofosbuvir/Velpatasvir, while 12 (30.0%) received Glecaprevir/Pibrentasvir. At the time of inclusion in the study, 36 patients were receiving opioid agonist maintenance therapy, whilst another 4 had just finished the treatment. 37.5% had a history of alcoholism and 42.5% received concomitant psychiatric treatment. All 40 patients (100.0%) completed the therapy cycle and 92.5% of patients adhered to the program. All patients tested negative for viral load at the end of the treatment. There were no significant drug interactions with common psychiatric treatments and no side effects were observed. The sustained virological response was achieved in 92.5% of cases with good tolerability, although two patients discontinued treatment temporarily. After HCV eradication, one patient died from an overdose, another from complications of cirrhosis, and one reinfection occurred. CONCLUSION Very high adherence to therapy and good tolerability was observed in our series of HCV patients treated at the SSUD, regardless of the substance abuse condition. Further validation in a larger population is required.

show abstract

Section: Discussionsupporting

confidence: 49%